Chlorambucil drug resistance in chronic lymphocytic leukemia: The emerging role of DNA repair

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 454-461

  Panasci, Lawrence ^a   Paiement, Jean Pierre ^a   Christodoulopoulos, Garyfallia ^a   Belenkov, Alexandre ^a   Malapetsa, Areti ^a   Aloyz, Raquel ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CHLORMETHINE; DNA; FLUDARABINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MELPHALAN; PROTEIN P53;

APOPTOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROSS RESISTANCE; DETOXIFICATION; DNA CROSS LINKING; DNA REPAIR; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; GENE MUTATION; GENETIC RECOMBINATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BIOLOGICAL TRANSPORT; CHLORAMBUCIL; CROSS-LINKING REAGENTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENES, P53; GLUTATHIONE; GLUTATHIONE TRANSFERASE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MECHLORETHAMINE; MODELS, GENETIC; MUTATION; RECOMBINATION, GENETIC;

EID: 0034899388     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Chronic lymphocytic leukemia: New insights into biology and therapy
2. Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance
3. In vitro chemosensitivity testing in chronic lymphocytic leukaemia patients
4. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs
5. Alkylating agents in clinical chemotherapy
6. The treatment of plasma cell myeloma
7. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer
8. Advanced ovarian adenocarcinoma
9. Mechanism of cyclophosphamide transport by L5178Y lymphoblasts in vitro
10. Studies with cyclophosphamide labeled with phosphorus-32: Nucleic acid alkylation and its effect on DNA synthesis in rat tumor and normal tissues
11. Analysis of melphalan adducts of 2′-deoxynucleotides in calf thymus DNA hydrolysates by capillary high-pressure liquid chromatography-electrospray tandem mass spectroscopy
12. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links
13. DNA crosslinking as an indicator of sensitivity and resistance of L1210 leukemia cells to cis-diaminedichloroplatinum (II) and L-phenylalanine mustard
14. Mechanism of melphalan resistance developed in vitro in human melanoma cells
15. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan
16. Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines
17. Dechlorination of L-phenylalanine mustard by sensitive and resistance tumor cells and its relationship to intracellular glutathione content
18. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion
19. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine
20. Isozyme specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines
21. Overexpression of metallothionein confers resistance to anticancer drugs
22. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
23. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells
24. A comparative analysis of drug-induced DNA effects in a nitrogen mustard resistant cell line expressing sensitivity in nitrosoureas
25. Reduced levels of drug-induced DNA cross linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity
26. Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia
27. DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance
28. Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes
29. Glutathione-associated enzymes in anticancer drug resistance
30. Expression of human μ or α class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: Effect on cellular sensitivity to cytotoxic agents
31. Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human a class glutathione S-transferase gene
32. Transfection of complementary DNAs for the heavy and light subunits of human γ-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan
33. Expression of a rat glutathione-S-transferase complementary DNA in rat mammary carcinoma cells: Impact upon alkylator-induced toxicity
34. Characterization of glutathione-S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients
35. Glutathione-S-transferase activity and multidrug resistance phenotype in chronic lymphocytic leukemia: Do they have any clinical relevance?
36. Drug resistance mechanisms in chronic lymphocytic leukemia
37. Glutathione S-transferase activity, sulfhydryl group and glutathione levels, and DNA cross-linking activity with chlorambucil in chronic lymphocytic leukemia
38. Molecular biology of chronic lymphocytic leukemia: Implications for therapy
39. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemo responses
40. High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukemia cells
41. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine
42. Regulation of clinical resistance by bcl-2 and bax oncoproteins in B-cell lymphocytic leukaemia
43. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones
44. p53 MDM-2 BAX, and BCL-2, and drug resistance in chronic lymphocytic leukemia
45. Relationship between nitrogen mustard drug resistance in B-cell chronic lymphocytic leukemia (B-CLL) and protein expression of Bcl-2, Bax, Bcl-X, and p53
46. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: Correlation with in vitro sensitivity to chlorambucil and purine analogs
47. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDRI/MDR3 gene expression
48. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
49. Chlorambucil in chronic lymphocytic leukemia: Mechanism of action
50. p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis
51. Interstrand cross-linking of DNA by difunctional alkylating agents
52. Synthesis of a duplex oligonucleotide containing a nitrogen mustard interstrand DNA-DNA cross-link
53. Detection of DNA cross-links in tumor cells with the ethidium bromide fluorescence assay
54. DNA filter elution: A window on DNA damage in mammalian cells
55. Principles and practice of DNA filter elution
56. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards
57. Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA crosslinks
58. In vivo DNA cross-linking by cyclophosphamide: Comparison of human lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells
59. Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases
60. Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards
61. Effect of alkyl-N-purine DNA glycosylase overexpression on cellular resistance to bifunctional alkylating agents
62. Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents
63. Defective DNA crosslink removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents
64. Cross-sensitivity of γ-ray-sensitive hamster mutants to cross-linking agents
65. The scid mutation in mice causes defects in the repair system for both double strand DNA breaks and DNA cross-links
66. Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination
67. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages
68. Evidence that mammalian cells possess homologous recombinational repair pathways
69. The contribution of homologous recombination in preserving genomic integrity in mammalian cells
70. The nuclear serine/threonine protein kinase DNA-PK
71. DNA-PK at the cross-roads of biochemistry and genetics
72. Rad51/RecA protein families and the associated proteins in eukaryotes
73. DNA repair activity in protein extracts of fresh human malignant lymphoid cells
74. The sensitivity of chronic lymphocytic leukaemia lymphocytes to irradiation in vitro
75. Human cells contain a DNA-activated protein-kinase that phosphorylates simian virus 40T antigen, mouse p53, and the human Ku autoantigen
76. Regulation of DNA-dependent protein kinase activity in leukemic cells
77. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards
78. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using Wortmannin
79. DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues
80. DNA-dependent protein kinase
81. DNA-dependent protein kinase catalytic subunit: A target for an ICE-like protease in apoptosis
82. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia
83. ATM mutations in B-cell chronic lymphocytic leukemia
84. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia
85. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia
86. Initiation of DNA interstrand crosslink repair in humans: The nucleotide excision repair system makes dual incisions 5′ to the cross-linked base and removes a 22- to 28-nucleotide-long damage-free strand
87. Studies of the interaction between Rad52 protein and the yeast single-stranded DNA binding protein RPA
88. Xrcc3 is required for assembly of Rad51 complexes in vivo
89. Mouse Rad54 affects DNA conformation and DNA-damaged induced Rad5l foci formation
90. Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes
91. Chlormabucil induction of HsRad51 in B-cell chronic lymphocytic leukemia
92. Binding of double-strand breaks in DNA by human Rad52 protein